Lung Cancer Clinical Trial
Official title:
The Effect of Smoking on Oral Microbiota
Background:
- Normal bacteria and other tiny organisms (the microbiota) live in the mouth and nose. They
contribute to human health in many ways, including digesting food and balancing hormones.
Testing samples from the mouth can show how microbiotas are related to health and disease.
However, the microbiota in a person's mouth differs depending on the methods of collection
and the part of the mouth that is tested. Understanding what can change the microbiota
(including mouth sites, and what a person eats or smokes) will give more information on how
to study oral microbiota and smoking-related cancers and other diseases.
Objectives:
- To see how smoking affects the microbiotas in mouth and nose.
- To determine which collection method for mouth specimens should be used for studying
microbiota.
Eligibility:
- Individuals at least 18 years of age who have been using tobacco products regularly for
at least 5 years.
- Individuals at least 18 years of age who have never smoked.
Design:
- Participants will be screened with a physical exam and medical history.
- Participants will have a dental exam. They will provide a saliva sample. The dentist
will take swabs from the inside of the mouth, including the tongue, tonsils, gums, and
teeth. The inside of the nose will also be swabbed.
- Participants will also fill out a questionnaire. It will ask about their history of
smoking and consumption of alcohol, tea, and coffee. It will also ask about current
medications, including antibiotics.
The oral microbial community (the microbiota), is centrally related to nutrition, metabolism,
immunity, inflammation, and endocrine balance. Cigarette smoking is associated with serious
health outcomes including cancer, cardiovascular disease and chronic lung disease. However,
little is known about the relationship between cigarette smoking, oral microbiota and
tobacco-related health outcomes. Microbiotas in the different sites of the same oral cavity
vary widely. Recent studies indicated that the difference in microbial profiles between
buccal mucosa and gingival plaque is as distinct as the difference between tongue and stool.
To date, knowledge about the effect of smoking on oral microbiotas is lacking. As an initial
step toward understanding the role of the oral microbiota in smoking-related health outcomes,
we propose a pilot study to evaluate the effects of cigarette smoking on the microbiotas in
buccal rinse obtained from the oral cavity and across 8 different oral cavity sites/niches
(saliva, swabs from tongue dorsum, hard palate, buccal mucosa, keratinized gingiva, palatine
tonsils, supragingival plaque, subgingival plaque). We will seek to recruit up to 50
volunteers through the Eastman Dental General Dentistry Clinic, Rochester, NY, including 25
current smokers with > 5 years of smoking history and 25 never smokers as a comparison group.
Age-group, gender, and race (Caucasian/African- American) will be matched for the two groups.
In each subject, the buccal cell (mouthwash) collection will be collected according to the
PLCO buccal cell collection protocol. In addition, collections across 8 different oral cavity
sites will be done using a protocol developed for the Human Microbiome Project. These 9
collections will be used for high throughput sequencing of 16S rRNA microbial genes at the
Institute of Genome Sciences, University of Maryland School of Medicine. The findings will
provide information about the effect of smoking on microbial taxa composition and relative
abundance at each collection site. This pilot study will demonstrate the effects of smoking
on oral microbiotas across different oral cavity sites and will also demonstrate which oral
collection site is most promising for the detailed study about cigarette smoking and oral
microbiota. In addition, the data collected will provide a validation framework to use the
PLCO buccal specimens for large-scale studies. The information about the validity of using
PLCO buccal cell collection will be an invaluable asset for further large scale studies of
the microbiota and cancer risk. We will also be able to investigate if there is any taxonomy
or microbial diversity difference between heavy smokers and never-smokers. This pilot study
will provide essential information about collection, design and analyses that will enable
further studies of the relationships between cigarette smoking, the oral microbiome and
tobacco-related cancers.
Under an Amendment, the participants will be contacted to provide another set of oral swabs
and mouthwash samples. The goal is to examine the stability or oral microbiota in 3-6 months
and confirm the results based on the first time point. The collection methods, assays and
analyses will be analogous to those performed previously.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|